Hostname: page-component-76fb5796d-45l2p Total loading time: 0 Render date: 2024-04-27T00:07:13.388Z Has data issue: false hasContentIssue false

Multiple system atrophy due to prolonged valproic acid treatment

Published online by Cambridge University Press:  23 April 2007

BARBARA BORRONI
Affiliation:
Neurology Unit, University of Brescia, Italy Email: bborroni@inwind.it
ANNA ROSATI
Affiliation:
Neurology Unit, University of Brescia, Italy Email: bborroni@inwind.it
CHIARA COSTANZI
Affiliation:
Neurology Unit, University of Brescia, Italy Email: bborroni@inwind.it
ROBERTO ZULLI
Affiliation:
Neurology Unit, University of Brescia, Italy Email: bborroni@inwind.it
DICRAM MARDIGHIAN
Affiliation:
Neurology Unit, University of Brescia, Italy Email: bborroni@inwind.it
ROBERTO GASPAROTTI
Affiliation:
Neurology Unit, University of Brescia, Italy Email: bborroni@inwind.it
ALESSANDRO PADOVANI
Affiliation:
Neurology Unit, University of Brescia, Italy Email: bborroni@inwind.it
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Studies reported in the literature indicate a wide range of movement disorders associated with anti-epileptic treatment (Easterford et al., 2004). Valproic acid is a well-known cause of reversible neurotoxicity characterized by symptoms resembling idiopathic Parkinson's disease (PD) and cognitive impairment (Armon et al., 1996; Onofrj et al., 1998).

Type
Letter
Copyright
International Psychogeriatric Association 2007